Neuphoria Therapeutics Inc. Financing Cash Flow
Neuphoria Therapeutics Inc. (NEUP) reported Financing Cash Flow of $17.92 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-09-18
- Neuphoria Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Neuphoria Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Neuphoria Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $14.66M.
- Neuphoria Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $3.25M.
- Neuphoria Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2026 was $17.92M, a 1072.29% increase from fiscal 2025.
- Neuphoria Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2025 was $1.53M, a 89.88% decline from fiscal 2024.
- Neuphoria Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2024 was $15.11M, a 291.58% increase from fiscal 2023.
- Neuphoria Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2023 was $3.86M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $0.00 derived: sum of 2 quarters · filed 2026-09-18 | $14.66M derived: sum of 3 quarters · filed 2026-09-18 | $17.92M 10-K · filed 2026-09-18 |
| 2026-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $14.66M derived: sum of 2 quarters · filed 2026-05-15 | $17.92M 10-Q · filed 2026-05-15 | $18.62M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | $14.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | $17.92M 10-Q · filed 2026-02-17 | $18.62M derived: sum of 3 quarters · filed 2026-09-18 | $19.78M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | $3.25M 10-Q · filed 2025-11-14 | $3.96M derived: sum of 2 quarters · filed 2026-09-18 | $5.12M derived: sum of 3 quarters · filed 2026-09-18 | $5.01M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | $704.67K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $1.87M derived: sum of 2 quarters · filed 2026-09-18 | $1.76M derived: sum of 3 quarters · filed 2026-09-18 | $1.53M 10-K · filed 2026-09-18 |
| 2025-03-31 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $1.05M derived: sum of 2 quarters · filed 2026-05-15 | $823.60K 10-Q · filed 2026-05-15 | $7.95M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$111.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$338.90K 10-Q · filed 2026-02-17 | $6.78M derived: sum of 3 quarters · filed 2026-02-17 | $8.53M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | -$227.34K 10-Q · filed 2025-11-14 | $6.89M derived: sum of 2 quarters · filed 2025-11-14 | $8.64M derived: sum of 3 quarters · filed 2025-11-14 | $14.27M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $7.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $8.87M derived: sum of 2 quarters · filed 2025-09-29 | $14.50M derived: sum of 3 quarters · filed 2025-09-29 | $15.11M 10-K · filed 2025-09-29 |
| 2024-03-31 | $1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-20 | $7.37M derived: sum of 2 quarters · filed 2025-05-20 | $7.99M 10-Q · filed 2025-05-20 | |
| 2023-12-31 | $5.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | $6.24M 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | $612.54K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $3.86M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |